News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cellceutix Signs Agreement for Kevetrin(TM) Safety Studies With Toxikon Corporation


11/2/2009 8:47:41 AM

BEVERLY, Mass., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCBB:CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease, today announced that is has concluded an agreement with Toxikon Corporation of Bedford, Massachusetts, to conduct the remaining preclinical studies required for an Investigational New Drug (IND) filing for its cancer drug Kevetrin(TM). The terms of the agreement were not disclosed. The studies covered by the agreement are designed to confirm that Kevetrin meets FDA safety requirements for studies in humans.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES